In the last trading session, 1.06 million Cardiff Oncology Inc (NASDAQ:CRDF) shares changed hands as the company’s beta touched 1.95. With the company’s per share price at $2.77 changed hands at -$0.13 or -4.48% during last session, the market valuation stood at $128.94M. CRDF’s last price was a discount, traded about -131.77% off its 52-week high of $6.42. The share price had its 52-week low at $0.94, which suggests the last value was 66.06% up since then. When we look at Cardiff Oncology Inc’s average trading volume, we note the 10-day average is 0.65 million shares, with the 3-month average coming to 473.61K.
Analysts gave the Cardiff Oncology Inc (CRDF) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CRDF as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Cardiff Oncology Inc’s EPS for the current quarter is expected to be -0.27.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Instantly CRDF was in red as seen at the end of in last trading. With action 5.32%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 87.16%, with the 5-day performance at 5.32% in the green. However, in the 30-day time frame, Cardiff Oncology Inc (NASDAQ:CRDF) is 3.36% up. Looking at the short shares, we see there were 6.83 million shares sold at short interest cover period of 14.11 days.
Cardiff Oncology Inc (CRDF) estimates and forecasts
Data shows that the Cardiff Oncology Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -36.47% over the past 6 months, a -8.60% in annual growth rate that is considerably lower than the industry average of 17.20%. Year-over-year growth is forecast to reach 8.60% up from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 80k. 5 analysts are of the opinion that Cardiff Oncology Inc’s revenue for the current quarter will be 80k. The company’s revenue for the corresponding quarters a year ago was 141k and 156k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -43.30%. The estimates for the next quarter sales put growth at -48.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 35.42%. The 2024 estimates are for Cardiff Oncology Inc earnings to decrease by -7.72%.
CRDF Dividends
Cardiff Oncology Inc is expected to release its next quarterly earnings report in November.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 7.25% of Cardiff Oncology Inc shares while 28.78% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 31.03%. There are 28.78% institutions holding the Cardiff Oncology Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 5.883% of the shares, roughly 2.63 million CRDF shares worth $5.84 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.7816% or 2.14 million shares worth $4.74 million as of 2024-06-30.
